Novo Nordisk A/S (NYSE:NVO) Stock Position Decreased by Harbour Capital Advisors LLC

Harbour Capital Advisors LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 11.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,649 shares of the company’s stock after selling 1,020 shares during the quarter. Harbour Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $670,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Raymond James & Associates raised its holdings in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after purchasing an additional 36,223 shares in the last quarter. Natixis Advisors LLC raised its holdings in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. International Assets Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after purchasing an additional 47,496 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE:NVO traded down $1.93 during mid-day trading on Monday, hitting $84.33. The company’s stock had a trading volume of 5,607,502 shares, compared to its average volume of 7,144,377. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average of $100.35 and a 200-day moving average of $119.04. The company has a market capitalization of $378.43 billion, a price-to-earnings ratio of 27.29, a P/E/G ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15.

Analyst Ratings Changes

Several brokerages have commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.